

New approaches to risk assessment of chemical mixtures

Toxicology Research and Application

Volume 3: 1–10

© The Author(s) 2019

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/2397847318820768

journals.sagepub.com/home/tor

A Wallace Hayes¹, Roman Li^{2,3}, Julia Hoeng³ , Anita Iskandar³,
Manuel C Peistch³, and Michael L Dourson⁴

Abstract

Assessing the risk of chemical mixtures is an intricate process that should integrate published laboratory data; comparisons with the composition, toxicity, and functionality of similar mixtures; complete analytical characterization of the mixture components; and *in silico* modeling. Various tiered assessment protocols have been proposed to address this need, and these protocols may be adapted on a case-by-case basis for both mixture-based and component-based evaluations. Emerging technologies have enabled rapid mixture testing in alternative animal models, such as human organotypic cultures and zebrafish. In addition, quantitative modeling that uses systems toxicology approaches can identify exposure-induced cellular and molecular alterations that would not be detected by standard toxicology assays. This review summarizes the approaches to risk assessment of complex chemical mixtures as presented at the Eighth International Congress of the Asian Society of Toxicology, June 2018.

Keywords

Additivity, harm reduction, hazard, heat-not-burn tobacco product, *in silico*, mixture, risk assessment, zebrafish

Date received: 25 November 2018; accepted: 27 November 2018

Strategies for the assessment of potential health impact of exposure to chemical mixtures

Humans are typically exposed to multiple chemicals rather than to single compounds, and various sources contribute to both simultaneous and sequential exposure to mixtures. The effects of these mixtures, however, are largely unknown. Chemical risk assessment is commonly conducted with isolated compounds without considering the potential interaction effects of mixtures of compounds. These effects can occur even when each compound is present at concentrations below the no-observed-adverse-effect level.^{1,2}

Assessing the risk of mixtures requires a proper risk assessment framework. Potential toxicity of a new mixture could be derived from data of similar mixtures if dose–response and mode-of-action data on the whole mixture are available. However, if such data are not available, component-based approaches can be leveraged. For a chemical mixture, the potential interactions between

components have been traditionally described as additive, synergistic, antagonistic, potentiating, inhibiting, or coalitive. These specifications, however, are typically applied to interactions between two chemicals. Therefore, as most mixtures contain multiple constituents, quantifying these interactions in terms of risk assessment is not an easy task.³

When sufficient safety information of a mixture is available from the literature, additional toxicology testing may not be necessary. Nevertheless, the characteristics of each

¹University of South Florida, Tampa, FL, USA

²Swiss Federal Institute of Aquatic Science and Technology (EAWAG), Dübendorf, Switzerland

³Philip Morris International (PMI) Research & Development, Neuchâtel, Switzerland

⁴Toxicology Excellence for Risk Assessment (TERA), Cincinnati, OH, USA

Corresponding author:

Julia Hoeng, Philip Morris International (PMI) Research & Development, Neuchâtel 2000, Switzerland.

Email: julia.hoeng@pmi.com



Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License

(<http://www.creativecommons.org/licenses/by/4.0/>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).




Figure 1. A strategic framework for the safety assessment of a cranberry leaf aqueous extract. There is limited work on the chemistry of cranberry leaf, although cranberry juice and cranberry extract are widely used. Because the leaf may have a different chemical profile than the fruit, an independent toxicity evaluation on the cranberry leaf is needed. The framework proposed by Booth and colleagues⁵ comprised various stages of assessment.

compound in a mixture can also vary considerably. Compounds such as food ingredients or natural extracts may differ by species, variant, part, growing/synthesis conditions, batch, pollution, location, harvest time and stage, handling practices, and storage conditions. For the evaluation of a compound with unknown toxicity, it is possible to establish a “chemical bridge” to existing toxicology data of a similar compound. If the two compounds share similar chemical compositions, manufacturing processes, and physicochemical properties, one may be able to forgo toxicity testing on the new compound. The sources of the two compounds may still vary naturally or be purified differently; however, this variability may be similar or within the variability observed between batches of the same chemical. Moreover, if the composition and functionality of the two compounds are equivalent, their differences may not be of toxicological concern.⁴

The scarcity of data on the toxicology of whole extracts or individual components of natural products (botanicals) makes safety determination challenging. A strategic framework for assessing the safety of natural products has been proposed by Booth and colleagues, who used cranberry leaf extract as a case study.⁵ Although cranberry juice and cranberry extract are used widely, there is limited work on the chemistry of cranberry leaf. Because the leaf may have a

different chemical profile than the fruit, an independent toxicity evaluation on the cranberry leaf is needed. The framework comprised various stages (Figure 1).⁵ Booth and colleagues demonstrated that using appropriate criteria, the cranberry leaf extract could be established as a food-grade raw material for use in manufacturing for use in food. Although the authors “were not aware of any publicly available toxicological databases allowing them to predict synergistic, additive, or antagonistic effects of naturally-occurring compounds found in a mixture,” such analytical evaluation can suggest the appropriate limits of detection at which naturally occurring toxins are out of concern.⁵ The European Food Safety Authority recently published a draft guidance⁶ on “harmonized methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals.” The harmonized framework is shaped based on the risk assessment phases (i.e. problem formulation, exposure assessment, hazard identification and characterization, and risk characterization, including uncertainty analysis). Booth and colleagues further specified that a set formula for dealing with safety evaluation of natural products does not exist and that each new submission must be dealt with on a case-by-case basis.⁵

In addition, Roe and colleagues had also proposed an industry strategy for the evaluation of the safety of

botanicals as dietary supplements.⁷ A part of the strategy was an *in silico* decision tree to address toxicity data gaps and to confirm the safe use of a botanical ingredient. When safety data are insufficient, one can address the data gap by utilizing both significant-human-use information and phytochemical constituent-based safety assessments to resolve toxicity end points of concern. By identifying and quantifying botanical constituents, food intake levels of the individual chemical constituent can thus be assessed using an *in silico* toxicology assessment tool for hazard identification. This decision tree approach can also bridge safety assessment between botanicals prepared using different methods (preparation and extractions). The decision tree uses multiple databases and information on structure–activity relationships to characterize the risks from individual constituents, establishing exposure thresholds for human use.

Evaluating mixture risk is a multistep process that includes mining published data and characterizing the mixture in the laboratory as well as *in silico* hazard analysis and modeling. Finally, the nature of the assessment may require the use of different approaches that should be determined on a case-by-case basis, which is particularly pertinent for the safety assessment of botanicals.

Systems toxicology approaches for chemical hazard assessment in zebrafish

Traditionally used by developmental biologists, zebrafish have gained recognition in the field of toxicology over the last few decades.^{8,9} This is largely due to some unique characteristics that this model possesses. The eggs are fertilized and undergo development and maturation *ex utero*, making it simple to administer defined concentrations of toxicants with precise timing. Zebrafish embryos and their protective chorions are transparent, permitting straightforward observation of any toxic effects on the cellular, organ, and organismal level. A single mating pair can produce hundreds of eggs per week that are easy and economical to maintain. The eggs develop into free-feeding larvae after 120 h postfertilization, consuming the yolk up to that point. This characteristic allows elimination of food addition, consumption, and digestion, which may be a confounding factor in toxicological assessments.

The above characteristics make zebrafish ideally suited for high-throughput screening, which can be performed in multiwell plates integrating automated exposure and screening,¹⁰ not unlike cell culture assays. Additionally, as only independently feeding animals are subject to regulation for animal experimentation in the European Union, early zebrafish embryos do not fall into the regulatory frameworks.¹¹ Unlike cultured cells, however, zebrafish embryos are intact vertebrates possessing functioning vertebrate organs, allowing the study of the cardiovascular, digestive, and central nervous systems. Owing to the organism's suitability for genetic manipulation, numerous zebrafish transgenic reporter lines are available for rapid organ

toxicity screening.^{12,13} Additionally, toxicant absorption, distribution, metabolism, and excretion can be investigated in zebrafish, because the larvae possess functional skin, gills, kidneys, livers, and guts.¹⁴ Seventy percent of human genes have zebrafish orthologs,¹⁵ and the hematopoietic,¹⁶ cardiovascular,¹⁷ and pancreatic¹⁸ physiologies are similar between humans and zebrafish. Pharmacology also appears to be largely conserved for diverse classes of drugs,^{19,20} suggesting that toxic effects exerted by chemicals in humans can be studied in fish.

The Organization for Economic Co-operation and Development has published a guideline for determining the acute toxicity of chemicals in embryonic stages of fish²¹; lethal and sublethal morphological end points are used to calculate lethal and effective concentrations for a given chemical. This has prompted major advances in the automation of methods such as embryo manipulation,²² imaging,²³ and behavioral measurements,²⁰ facilitating phenotype discovery and high-throughput toxicity testing in an *in vivo* vertebrate system.

Assessing chemical mixtures in the developing fish and identifying transcriptional markers are relatively straightforward²⁴ and may help identify synergistic toxic effects that are difficult to foresee²⁵ or detect drivers of toxicity in the mixture.²⁶ Many zebrafish screens rely on phenotypical observations to infer toxicity, but, as with any phenotype-based screening, the mechanism of action is difficult to decipher from such data. Matching phenotypes between chemicals with a known mechanism of action and chemicals or mixtures with no known targets can be used to infer the mechanism.²⁷ Phenotype matching between known genetic mutations and chemicals has also been used successfully to identify chemical targets.²⁸ This approach, however, is labor-intensive, because it relies heavily on data generated from mutant or chemically exposed fish. Cellular and behavioral phenotypes must be defined in sufficient detail to capture subtle chemical toxicities.

Transcriptomic approaches have become reliable and economically viable as part of a chemical toxicity analysis,²⁹ but they present their own challenges. Protein activity, such as folding, localization, and posttranslational modifications in the presence of binding partners, is not captured in a transcriptomic experiment. Therefore, a toxicity assessment based on transcriptomic data alone may result in a significant number of false negatives. Proteomics and metabolomics address this issue to an extent, although these methods are relatively challenging, less reliable, and more expensive than transcriptomic approaches, with limited coverage of the proteome³⁰ or metabolome.³¹ Developments in systems toxicology may address these limitations (Figure 2). Systems toxicology measures molecular changes within organ systems, using computational analyses to identify causal molecular events that lead to adverse outcomes.³² This approach relies on a causal biological network, a collection of computable statements curated from scientific literature that describe molecular




Figure 2. A systems toxicology approach to analyzing chemical and chemical mixture toxicity in zebrafish. Organ-specific transcriptomic analysis following exposure generates data for computations of biological network impact. The results are used to generate mechanistic hypotheses. Together with apical end points, this approach can be used to decipher the chains of molecular events leading to adverse outcomes.

pathways within organ systems.³³ Biological entities, including mRNA, proteins, protein activities, biological processes, and diseases, are represented by nodes within the network. The nodes are connected by directed relationships, such as upregulation or inhibition, giving the network a cause-and-effect topology. Nodes within the network are then assigned information about downstream transcript abundance. Downstream transcripts are mRNAs that are known to be regulated by the corresponding upstream node. This information is either manually curated from literature or gathered from publicly available transcriptomic data sets. Transcriptomic data from organisms exposed to chemical mixtures can be used next to infer whether the upstream node was activated or inhibited. By performing this analysis for all scorable nodes within a biological network, it is possible to calculate the perturbation of the network by a chemical or a chemical mixture and to decipher the molecular pathways that lead to adverse outcomes.³⁴ If the same pathways are found in mammals, mechanisms of toxicity can be extrapolated to higher vertebrates, including humans (Figure 2).

The advantages of a network-based approach are as follows. (1) Multiple biological outcomes and entities, from RNA to protein to pathology, may be measured during a single transcriptomic experiment without the need for

proteomics or metabolomics. (2) The assumption that mRNA abundance corresponds to protein activity is avoided. (3) Networks are organ system-specific, allowing for the assessment of toxicity for distinct organs. (4) Because networks are directed, it is easy to visualize a chain of molecular events that lead to adverse outcomes. (5) Perturbation of the entire network can be quantified, giving a numerical measure of toxicity. (6) Networks permit the analysis of the effects of chemical mixtures, which may perturb multiple pathways.

Zebrafish studies in environmental toxicology,³⁵ drug discovery,³⁶ and drug toxicity³⁷ have demonstrated that this organism is a valuable tool in biomedical research. The assessment of the mechanism of action of chemicals, chemical mixtures, and medicines afforded by the network biology approach may lead to more accurate environmental and human risk assessment and faster discoveries of safer pharmaceuticals. The next step toward this goal will be to build zebrafish-specific biological networks that describe pathways leading to organ toxicity.

In vitro approaches for assessment of complex aerosol mixtures

Smoking causes serious conditions such as lung cancer and chronic obstructive pulmonary disease. Philip Morris

International (PMI) is developing novel products with the potential to reduce individual risk and population harm in comparison with smoking cigarettes and is conducting extensive and rigorous mechanistic studies to assess their biological impact vis-à-vis that of reference cigarettes. Reducing harm requires the availability of reduced-risk products that are accepted by users and can be accomplished by replacing cigarettes with such products (the effects of which on health should be as close to smoking cessation as possible).

The desire to move away from animal testing has been the impetus for developing advanced cell culture models, although findings from *in vitro* studies may not be interpreted or extrapolated in a straightforward manner in the context of *in vivo* effects. Thus, relevant biological test systems are needed to facilitate an accurate identification of biomarkers of exposure, response, and disease. For testing inhaled mixtures, *in vitro* studies may be conducted using submerged cultures or air-liquid interface (ALI) cultures. Although easier to handle, submerged cultures are not suitable for toxicity testing of inhaled compounds. ALI cultures enable direct exposure of cells and tissues to inhalable gases and aerosols, unlike testing protocols in two-dimensional submerged airway cultures, where liquid fractions or extracts of the smoke or aerosol of interest must be generated and applied. These fractions do not typically represent the entire chemical composition of the smoke or aerosol.

Various exposure systems are available for testing inhaled aerosols, including those manufactured by Vitrocell Systems, Borgwaldt, and Cultex Laboratories.³⁸ These systems must include modules that ensure the functionality of all steps in the process: generation of smoke or aerosol, although it can be accomplished manually, should be consistent; dilution of the smoke or aerosol must be fast and reproducible; and dose monitoring should be accurate. The last of these typically employs time-of-flight mass spectrometry for the gas phase and photometry, and microbalances for the particle phase, although the concentrations of deposited compounds can be monitored further. The aerosols must also be characterized for accurate computation of aerosol deposition rate, the mixing efficiency of the dilution system, the aerosol's stability in the dilution system, and the influence of operating conditions and physical mechanisms. Finally, auxiliary equipment can be incorporated to control vacuum and dilution air flow rates, temperature, and humidity.³⁹

More than 6000 constituents have been identified in cigarette smoke, and many of these are formed during the combustion process.⁴⁰ Some constituents are harmful or potentially harmful, and it is unknown which of them are responsible for tobacco-related disease.⁴¹ The lower temperatures and lack of combustion in heat-not-burn tobacco products reduce the number of constituents in the aerosol, and nicotine is transferred by distillation.

PMI has carried out a series of *in vitro* studies using human organotypic epithelium cultures (nasal, buccal, and bronchial) to assess a heat-not-burn tobacco product, the Tobacco Heating System (THS) 2.2, in comparison with a reference cigarette.⁴² The Vitrocell[®] Exposure System (Vitrocell Systems GmbH, Waldkirch, Germany) was used to deliver aerosols to ALI cultures of human primary epithelial cells, and end points of interest were captured after the exposure by measuring mediators secreted into the basolateral medium and by histological analysis. The biological impacts of exposure to THS 2.2 aerosol were compared with those of exposure to reference cigarette smoke for culture morphology, secretion of inflammatory mediators, and differential gene expression. At similar nicotine concentrations in the THS 2.2 aerosol and reference cigarette smoke, the average reduction in the formation of harmful and potentially harmful constituents in THS 2.2 aerosol compared with constituents in reference cigarette smoke was 95%.⁴¹ Pronounced alterations in culture morphology were seen following exposure to reference cigarette smoke but not to THS 2.2 aerosol (Figure 3). Levels of pro-inflammatory mediators, such as VEGFA, TIMP1, MMP-1, CXCL8, CXCL10, IL-6, IL1 β , and CSF2, were much lower in cultures exposed to THS 2.2 aerosol than in cultures exposed to cigarette smoke. The THS 2.2 aerosol exposure elicited differential regulation of fewer genes than did the cigarette smoke exposure, and this differential regulation was mostly limited to the earliest post-exposure time points assessed, suggesting a lower and more transient response to the exposure.⁴²⁻⁴⁴

These *in vitro* studies were conducted following a systems toxicology approach, allowing us to detect the underlying perturbation of cellular and molecular signals that would not be evident morphologically. Systems toxicology integrates traditional laboratory testing with quantitative modeling of large data sets to identify the biological networks affected by an exposure and the molecular pathways involved and to infer the adverse outcomes.⁴³ The approach involves a robust experimental design to generate reproducible empirical global gene expression data and to identify and quantify the biological networks perturbed by the exposure (Figure 3). In all cultures tested (nasal, buccal, and bronchial), similar molecular entities and networks were perturbed; these were the networks governing cell fate, cell proliferation, cell stress, and inflammatory processes. The xenobiotic metabolism response was elicited by exposure to cigarette smoke but had only a minor and mainly transient impact on cultures exposed to THS 2.2 aerosol.⁴²⁻⁴⁴

A similar approach to that used for THS 2.2 could be leveraged for assessing electronic cigarettes (e-cigarettes), one type of electronic nicotine delivery system. The popularity of e-cigarettes has grown tremendously in recent years, but assessing the potential toxicity of e-cigarettes presents multiple challenges involving a lack of standards in (1) analytical methods, (2) the testing of flavoring




Figure 3. Systems toxicology approach for an *in vitro* assessment of cigarette smoke and THS 2.2 aerosol exposures. Representative images showing the histology sections of human organotypic buccal, bronchial, and nasal cultures following exposure to cigarette smoke or THS 2.2 aerosol (left panel). Biological impact scores shown as radar charts reflecting the perturbation scores of biological network model families (cell fate, cell proliferation, cell stress, and inflammatory process network) following exposure to cigarette smoke or THS 2.2 aerosol (right panel). Adapted from a previous publication.⁴² THS: Tobacco Heating System.

compounds, (3) aerosol generation protocols, and (4) selecting the chemicals to monitor.^{45,46} Multiple *in vitro* studies have compared biological responses in human bronchial epithelial cultures exposed to reference cigarette smoke and to e-cigarette vapor and found reduced cytotoxicity in human cell cultures exposed to e-cigarette vapor^{47,48} as well as a reduced impact of gene expression⁴⁹; these limited effects are believed to result from the lower temperatures and lack of combustion.⁵⁰ In comparison with cigarette smoke, e-cigarette vapor has been shown to elicit only limited mutagenicity,⁵¹ although it can induce measurable levels of oxidative stress and inflammatory mediators,⁴⁸ and the composition of added flavoring compounds may modulate toxic responses.⁵² Nevertheless, doses that are physiologically relevant and reflect real-world use should be assessed to better predict the potential toxicity of e-cigarette use. Furthermore, in the context of harm reduction, e-cigarette assessment should include a comparison with a combustible tobacco product.⁵³

PMI has established the INTERVALS platform (<http://intervals.science>) to demonstrate the scientific rigor, thoroughness, precision, and transparency required to assess

the inhalation toxicology of potential reduced-risk products in support of designing a smoke-free future. The platform promotes independent, third-party analyses and collaborations by sharing protocols, data, and tools. Raw data, reports, and detailed laboratory protocols from preclinical and clinical studies of potential reduced-risk products are shared freely. With the rapid evolution of heated tobacco products and e-cigarettes, collaborative efforts between the scientific community, industry, and regulatory stakeholders are needed. Such efforts will also facilitate the adoption of 21st-century approaches for toxicity testing.

New tiered risk assessment approaches of mixtures

The challenges in assessing the risk of exposure to mixtures involve consideration of aggregate risk (exposure to a single chemical from multiple sources), cumulative risk (exposure to multiple agents), and the interaction of exposures to multiple chemicals that, in combination, generate risk other than the sum of their single-agent exposure risks. Assessing whole mixtures involves toxicity profiles,




Figure 4. Tiered framework for exposure assessment, hazard evaluation, and risk characterization. A conceptual representation of a tiered framework, reproduced from a previous publication.⁵⁷

epidemiological investigations, and generating hazard quotients.

In cases where the mixture's mode of action is unknown, information on the mode of action of each constituent is gathered, along with consideration of structure–activity similarities and possible interactions. The US Environmental Protection Agency (EPA) (2000)⁵⁴ and European Union (2011)⁵⁵ have issued guidance documents on evaluating chemical mixtures. Both texts emphasize development of an assessment on the basis of whether information is available on the mixture of concern. In the EPA guidance, this question is extended to mixtures that are sufficiently similar. If information is not available on the mixture or a sufficiently similar mixture, both documents emphasize constituent-based assessment. When evaluating individual components, both guidance documents consider whether chemical interactions are suspected between constituents. If they are, a case-by-case assessment that is based on the observed synergism or antagonism is generally recommended. If interactions are not suspected, an additivity assessment is conducted by either dose addition, if the modes of action are similar, or by response addition, if the modes of action are dissimilar.

Data-driven approaches to mixture assessment leverage information on exposure, dose–response, and mode of action. When this information is available for the mixture

being studied, the mixture is considered as a whole, and toxicity values, such as cancer slope factors, minimum risk levels, and reference doses and concentrations, can be estimated. When information on the mixture, or in the case of EPA a similar mixture, is not available, a component-based approach is used instead, and the toxic effects and mode of action of each component of the mixture are compared.

These approaches are based on tiered assessments that consider exposure and hazard in an integrative and iterative manner in each tier. Meek and colleagues⁵⁶ have proposed a four-tier framework that can be used in both mixture- and component-based investigations. Each of the four tiers proposed includes exposure assessment, hazard evaluation, and risk characterization, and each tier provides a more refined and specific assessment than the preceding tier (Figure 4). Information from different levels of biological organization can be incorporated into the model as well as analyses of factors such as mode of action and species concordance.⁵⁷

Another multistep approach to mixture evaluation is the dose additivity combined prediction model proposed by Hertzberg and colleagues.⁵⁸ If the mixture's components are known to be toxicologically similar, if their dose–response curves are geometrically congruent, and if the predicted mixture response follows that of each component, the mixture is treated as dose-additive and can be

represented as a linear combination of its constituents' doses. To evaluate dose additivity in a specific mixture in this four-step approach, the assessment considers how well the model fits the data on constituent chemicals (step 1) and the data on the mixture as a whole (step 2), the agreement between the model and the mixture data (step 3), and the consistency between the model and other mixture models (step 4).⁵⁸

High-throughput screening can provide information on biological activity that, when combined with chemical characterization, enables the implementation of similarity approaches and prototype mixtures for hazard assessment.⁵⁹ Because *in vivo* testing in mammals is not logistically feasible, high-throughput testing in alternative model organisms, such as zebrafish, could be integrated into risk assessment.

Both *in vitro* and *in silico* comparative approaches begin with analytical characterization of mixture composition and toxicity. Each identified constituent is processed through a decision tree to close safety gaps, inform supportable exposure levels, and determine the need for safety studies. The variables involved, biological activity, and mode of action can be estimated. New methods offer a significant improvement in assessing the hazards of chemical mixtures. Coupled with appropriate exposure determination, these *in vitro* modeling tools can promote a credible estimate to the *in vivo* toxicity outcome.

Summary

Evaluating the risk from chemical mixtures is a multifaceted task that presents multiple challenges and requires an appropriate assessment framework. Depending on the available data, whole mixture approaches or component-based approaches, or a combination of both, can be used. *In silico* modeling and decision trees can facilitate the risk assessment of mixtures. *In vivo* testing using animal models is not always logistically feasible, but high-throughput testing in alternative models, such as organotypic *in vitro* models and zebrafish, can be integrated into the assessment. Apart from classical toxicology testing methods, risk assessment can further leverage omics approaches such as transcriptomics, proteomics, and metabolomics to reveal the mode of action. In addition, a network-based systems toxicology approach, which utilizes quantitative modeling of data sets to identify the biological networks perturbed by a given exposure and the underlying molecular pathways involved, will facilitate the biological interpretation of omics data. Finally, various tiered assessment strategies have been proposed that incorporate laboratory data and computational modeling for robust investigation into the risk posed by chemical mixtures. These emerging tools and protocols will lead to a significant improvement in the hazard assessment of complex mixtures and should continue to promote credible protection of public health.

Authors' note

Some of the information in this review was previously presented at the Eighth International Congress of the Asian Society of Toxicology (ASIATOX) in Pattaya, Thailand, on 18 June 2018.

Acknowledgements

The authors thank Dean Meyer, PhD, of Edanz Medical Writing for providing medical writing support, which was funded by Philip Morris International.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JH, AI, RL are employees of Philip Morris International.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Julia Hoeng  <https://orcid.org/0000-0001-5371-6801>

References

1. Kortenkamp A and Faust M. Regulate to reduce chemical mixture risk. *Science* 2018; **361**: 224–226.
2. Thrupp TJ, Runnalls TJ, Scholze M, et al. The consequences of exposure to mixtures of chemicals: something from “nothing” and “a lot from a little” when fish are exposed to steroid hormones. *Sci Total Environ* 2018; **619**: 1482–1492.
3. Hertzberg RC and MacDonell MM. Synergy and other ineffective mixture risk definitions. *Sci Total Environ* 2002; **288**: 31–42.
4. The Food and Drug Administration (FDA). Food additives permitted for direct addition to food for human consumption: glycerol ester of gum rosin. 21C.F.R. § 172.735; Revised as of April 1, 2018.
5. Booth NL, Kruger CL, Hayes AW, et al. An innovative approach to the safety evaluation of natural products: cranberry (*Vaccinium macrocarpon* Aiton) leaf aqueous extract as a case study. *Food Chem Toxicol* 2012; **50**: 3150–3165.
6. European Food Safety Authority. Draft guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals, <https://www.efsa.europa.eu/sites/default/files/consultation/consultation/180626-1-ax1.pdf> (2018, accessed 29 October 2018).
7. Roe AL, McMillan DA and Mahony C. A tiered approach for the evaluation of the safety of botanicals used as dietary supplements: an industry strategy. *Clin Pharmacol Ther* 2018; **104**: 446–457.
8. Gamse JT and Gorelick DA. Mixtures, metabolites, and mechanisms: understanding toxicology using zebrafish. *Zebrafish* 2016; **13**: 377–378.
9. Tanguay RL. The rise of zebrafish as a model for toxicology. *Toxicol Sci* 2018; **163**: 3–4.

10. Reif DM, Truong L, Mandrell D, et al. High-throughput characterization of chemical-associated embryonic behavioral changes predicts teratogenic outcomes. *Arch Toxicol* 2016; **90**: 1459–1470.
11. Strähle U, Scholz S, Geisler R, et al. Zebrafish embryos as an alternative to animal experiments—a commentary on the definition of the onset of protected life stages in animal welfare regulations. *Reprod Toxicol* 2012; **33**: 128–132.
12. Burns CG, Milan DJ, Grande EJ, et al. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. *Nat Chem Biol* 2005; **1**: 263.
13. Zhang X, Li C and Gong Z. Development of a convenient in vivo hepatotoxin assay using a transgenic zebrafish line with liver-specific DsRed expression. *PLoS One* 2014; **9**: e91874.
14. Nishimura Y, Murakami S, Ashikawa Y, et al. Zebrafish as a systems toxicology model for developmental neurotoxicity testing. *Congenit Anom* 2015; **55**: 1–16.
15. Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. *Nature* 2013; **496**: 498.
16. Jagannathan-Bogdan M and Zon LI. Hematopoiesis. *Development* 2013; **140**: 2463–2467.
17. Asnani A and Peterson RT. The zebrafish as a tool to identify novel therapies for human cardiovascular disease. *Dis Model Mech* 2014; **7**: 763–767.
18. Tiso N, Moro E and Argenton F. Zebrafish pancreas development. *Mol Cell Endocrinol* 2009; **312**: 24–30.
19. Milan DJ, Peterson TA, Ruskin JN, et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. *Circulation* 2003; **107**: 1355–1358.
20. Rihel J, Prober DA, Arvanites A, et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. *Science* 2010; **327**: 348–351.
21. OECD. *Test No. 236: Fish Embryo Acute Toxicity (FET) Test*. Paris: OECD, 2013.
22. Mandrell D, Truong L, Jephson C, et al. Automated zebrafish chorion removal and single embryo placement: optimizing throughput of zebrafish developmental toxicity screens. *J Lab Autom* 2012; **17**: 66–74.
23. Pardo-Martin C, Chang T-Y, Koo BK, et al. High-throughput in vivo vertebrate screening. *Nat Methods* 2010; **7**: 634.
24. Crago J and Klaper R. Place-based screening of mixtures of dominant emerging contaminants measured in Lake Michigan using zebrafish embryo gene expression assay. *Chemosphere* 2018; **193**: 1226–1234.
25. Ginzburg AL, Truong L, Tanguay RL, et al. Synergistic toxicity produced by mixtures of biocompatible gold nanoparticles and widely used surfactants. *ACS Nano* 2018; **12**(6): 5312–5322.
26. Geier MC, Minick DJ, Truong L, et al. Systematic developmental neurotoxicity assessment of a representative PAH Superfund mixture using zebrafish. *Toxicol Appl Pharm* 2018; **354**: 115–125.
27. Kokel D, Bryan J, Laggner C, et al. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. *Nat Chem Biol* 2010; **6**: 231.
28. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. *Nat Chem Biol* 2008; **4**: 33.
29. Williams TD, Mirbahai L and Chipman JK. The toxicological application of transcriptomics and epigenomics in zebrafish and other teleosts. *Brief Funct Genomics* 2014; **13**: 157–171.
30. Vogel C and Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. *Nat Rev Genet* 2012; **13**: 227.
31. Markley JL, Bruschweiler R, Edison AS, et al. The future of NMR-based metabolomics. *Curr Opin Biotech* 2017; **43**: 34–40.
32. Sturla SJ, Boobis AR, FitzGerald RE, et al. Systems toxicology: from basic research to risk assessment. *Chem Res Toxicol* 2014; **27**: 314–329.
33. Hoeng J, Deehan R, Pratt D, et al. A network-based approach to quantifying the impact of biologically active substances. *Drug Discov Today* 2012; **9**: 413–418.
34. Martin F, Sewer A, Talikka M, et al. Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models. *BMC Bioinformatics* 2014; **15**: 238.
35. Horzmann KA and Freeman JL. Making waves: new developments in toxicology with the zebrafish. *Toxicol Sci* 2018; **163**: 5–12.
36. MacRae CA and Peterson RT. Zebrafish as tools for drug discovery. *Nat Rev Drug Discov* 2015; **14**: 721.
37. McGrath P and Li C-Q. Zebrafish: a predictive model for assessing drug-induced toxicity. *Drug Discov Today* 2008; **13**: 394–401.
38. Thorne D and Adamson J. A review of in vitro cigarette smoke exposure systems. *Exp Toxicol Pathol* 2013; **65**: 1183–1193.
39. Behrsing H, Hill E, Raabe H, et al. In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: workshop proceedings, conclusions and paths forward for in vitro model use. *Altern Lab Anim* 2017; **45**: 117–158.
40. Rodgman A and Perfetti TA. *The chemical components of tobacco and tobacco smoke*. 2nd ed. Boca Raton: CRC Press, 2013.
41. Smith MR, Clark B, Lüdicke F, et al. Evaluation of the Tobacco Heating System 2.2. Part 1: description of the system and the scientific assessment program. *Regul Toxicol Pharm* 2016; **81**: S17–S26.
42. Iskandar AR, Titz B, Sewer A, et al. Systems toxicology meta-analysis of in vitro assessment studies: biological impact of a candidate modified-risk tobacco product aerosol compared with cigarette smoke on human organotypic cultures of the aerodigestive tract. *Toxicol Res* 2017; **6**: 631–653.
43. Iskandar AR, Mathis C, Martin F, et al. 3-D nasal cultures: systems toxicological assessment of a candidate modified-risk tobacco product. *ALTEX-Altern Anim Ex* 2017; **34**: 23–48.
44. Zanetti F, Sewer A, Mathis C, et al. Systems toxicology assessment of the biological impact of a candidate modified

- risk tobacco product on human organotypic oral epithelial cultures. *Chem Res Toxicol* 2016; **29**: 1252–1269.
45. Iskandar AR, Gonzalez-Suarez I, Majeed S, et al. A framework for in vitro systems toxicology assessment of e-liquids. *Toxicol Mech Method* 2016; **26**: 392–416.
 46. Flora JW, Meruva N, Huang CB, et al. Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. *Regul Toxicol Pharm* 2016; **74**: 1–11.
 47. Azzopardi D, Patel K, Jaunky T, et al. Electronic cigarette aerosol induces significantly less cytotoxicity than tobacco smoke. *Toxicol Mech Method* 2016; **26**: 477–491.
 48. Vasanthi Bathrinathan P, Brown JE, Marshall LJ, et al. An investigation into E-cigarette cytotoxicity in-vitro using a novel 3D differentiated co-culture model of human airways. *Toxicol In Vitro* 2018; **52**: 255–264.
 49. Haswell LE, Baxter A, Banerjee A, et al. Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics. *Sci Rep* 2017; **7**: 888.
 50. Takahashi Y, Kanemaru Y, Fukushima T, et al. Chemical analysis and in vitro toxicological evaluation of aerosol from a novel tobacco vapor product: a comparison with cigarette smoke. *Regul Toxicol Pharm* 2018; **92**: 94–103.
 51. Tommasi S, Bates SE, Behar RZ, et al. Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro. *Lung Cancer* 2017; **112**: 41–46.
 52. Bengalli R, Ferri E, Labra M, et al. Lung toxicity of condensed aerosol from E-CIG liquids: influence of the flavor and the in vitro model used. *Int J Env Res Pub He* 2017; **14**: 1254.
 53. Bullen C, López-Núñez C and Knight-West O. E-cigarettes in smoking cessation: a harm reduction perspective. *Clinical Pharmacist* 2016; **8**(4): 123–127.
 54. Hertzberg R, Choudhury H, Rice G, et al. *Supplementary guidance for conducting health risk assessment of chemical mixtures*. Washington: Risk Assessment Forum Technical Panel, 2000.
 55. (SCENIHR) SCoEaNIHR. *Toxicity and assessment of chemical mixtures*. Brussels: European Union, 2011, p. 50.
 56. Meek M, Boobis AR, Crofton KM, et al. Risk assessment of combined exposure to multiple chemicals: a WHO/IPCS framework. *Regul Toxicol Pharmacol* 2011; **60**: S1–S14.
 57. Meek M, Boobis A, Cote I, et al. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. *J Appl Toxicol* 2014; **34**: 1–18.
 58. Hertzberg RC, Pan Y, Li R, et al. A four-step approach to evaluate mixtures for consistency with dose addition. *Toxicology* 2013; **313**: 134–144.
 59. National Toxicology Program. Toxicology in the 21st Century (Tox21), <https://ntp.niehs.nih.gov/results/tox21/index.html> (2018, accessed 29 October 2018).